Company: ACBM
Filing Date: 2025-07-11
Form Type: 10-Q
Source: 0001640334-25-001169
Chunk: 16

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-11
Form: 10-Q
Item: Item 1
Chunk 16
---
 statements.

 4Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Operations

(Unaudited)

  Three Months Ended   Nine Months Ended   September 30,  September 30,   2023  2022  2023  2022              Revenues $-  $-  $-  $298,500 Cost of revenues  -   -   -   222,000 Gross profit  -   -   -   76,500                  Operating expenses                Selling, general and administrative   700,150   1,490,823   3,500,141   4,452,343 Research and development  396,550   2,520,000   4,794,825   7,560,000 Provision for doubtful accounts  480,000   -   480,000   - Provision for purchase deposit write-off  12,000   -   12,000   - Total operating expenses  1,588,700   4,010,823   8,786,966   12,012,343                  Loss from operations  (1,588,700)  (4,010,823)  (8,786,966)  (11,935,843)                 Other expense                Interest expense - related party  790   499   2,367   919 Total other expenses  790   499   2,367   919                  Loss before income tax expense  (1,589,490)  (4,011,322)  (8,789,333)  (11,936,762)Income tax expense   -   -   -   - Net loss $(1,589,490) $(4,011,322) $(8,789,333) $(11,936,762)                 Basic and diluted loss per share of common stock $(0.03) $(0.07) $(0.15) $(0.20)                 Weighted average number of shares of common stock outstanding  60,042,000